NCT01454024View on ClinicalTrials.gov

Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

1,031

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Delivery Systems
Interventions
DEVICE

FlexPen®

Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice

DEVICE

NovoPen® 3

Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice

Trial Locations (1)

Unknown

Karachi

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY